Background. Our knowledge of the susceptibility genes for pheochromocytomas/paragangliomas has increased; however, data on its impact on surgical decision-making has not been described. The aim of this study was to determine the effect of routine preoperative genetic testing on the operative intervention in patients with pheochromocytomas/paragangliomas. Methods. One-hundred-eight patients diagnosed with pheochromocytomas/paragangliomas who underwent 118 operations had preoperative genetic testing for 9 known pheochromocytoma/paraganglioma susceptibility genes. A retrospective analysis of a prospective database was performed to evaluate clinical factors associated with the surgical approach selected and the outcome of the surgical intervention. Results. In 51 patients (47%), a germline mutation was detected and one-third had no family history of pheochromocytoma/paraganglioma. In 77 operations (65%), it was the first operative intervention for the disease site (60 laparoscopic, 17 open), and 41 (35%) were reoperative interventions (36 open, 5 laparoscopic). For initial operations, variables associated with whether an open or laparoscopic approach was used were tumor size (P = .009) and presence of germline mutation (P = .042). Sixty-eight adrenal operations were performed (54 total, 14 cortical-sparing). Variables significantly associated with a corticalsparing adrenalectomy being performed were the presence of germline mutation (P = .006) and tumor size (P = .013). Conclusion. Preoperative knowledge of the germline mutation status affects the surgical approach and extent of adrenalectomy.
Pheochromocytoma (PC) is a tumor that originates from chromaffin cells of the adrenal medulla, while paraganglioma (PGL) arises from the chromaffin cells of sympathetic and parasympathetic ganglia, as defined by the World Health Organization (WHO). PC/ PGL is present in 0.1-0.6% of patients with hypertension and is found in 0.05% of patients during autopsy. 1 Most PCs/PGLs hypersecrete catecholamines and their metabolites, which may cause difficultto-control hypertension, diabetes mellitus, and cardiovascular morbidity. 2 Patients may also present with an incidentally discovered mass or with vague symptoms, which include diaphoresis, headaches, palpitations, and anxiety. 1 PC/PGL may be sporadic or inherited. Inherited PC/PGL syndromes include neurofibromatosis type 1 (NF1), multiple endocrine neoplasia type 2, von Hippel-Lindau syndrome (VHL), myc-associated factor X (MAX), and familial PC/PGL with succinate dehydrogenase mutations. There has been considerable progress made in our knowledge of the susceptibility genes that predispose to PCs/ PGLs, and there are 12 well-known germline mutations related to these tumors. The germline mutations occur in the following genes: RET, VHL, NF1, SDHA-D, MAX, FH, KIF1β, SDHAF2, and TMEM127. 3 The frequency of germline mutation in patients with PC/PGL is up to 40% in patients of all ages and can be as high as 80% in the pediatric population. 4 There is no data on preoperative genetic testing and its impact on the surgical treatment of PC/PGL. The aim of this study was to determine if routine preoperative genetic testing was associated with the type of operative intervention and the extent of adrenalectomy used in patients with PC/PGL and to determine the rate of clinically unknown inherited PC/PGL.
Methods
One hundred eight patients diagnosed with PC/PGL underwent resection of their tumors at the National Institutes of Health Clinical Center between November 2009 and September 2016. After informed consent was obtained, all patients were enrolled in clinical protocols (NCT00004847, NCT01005654). The study was approved by the institutional review boards of the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Cancer Institute. Only patients with a histologic diagnosis of PC/PGL were included in the study. The operations were classified into first-time operations and reoperations. A reoperation was defined as having a previous operation at the same site as the newly diagnosed tumor. Preoperative genetic testing was performed for known PC/PGL susceptibility genes (RET, VHL, NF1, SDHA-D, MAX, and FH) in a Clinical Laboratory Improvement Amendments certified laboratory.
We performed a retrospective analysis of prospectively collected data on demographic characteristics (age, sex, and ethnicity/ race), clinical data (body mass index, operative approach, operative duration, the extent of adrenalectomy, tumor size, and pathologic diagnosis), and genetic testing results, as well as laboratory data including preoperative and postoperative 24-hour urine and plasma dopamine, epinephrine, norepinephrine, free metanephrine, and free normetanephrine. Patients with laboratory values elevated to 2 times the upper limit of normal or higher were considered to have functional tumors. Biochemical remission was defined as a postoperative laboratory value <2 times the upper limit of normal in patients with a functional tumor on a preoperative evaluation.
Statistical analysis
Univariate analysis using Spearman's correlation coefficient, Student t test, and χ 2 tests and multivariate analysis using logistic regression were performed. We analyzed demographic characteristics, clinical factors, and genetic information to evaluate their impact on the surgical approach selected and the extent of adrenalectomy. Two-tailed P values were used and reported. IBM SPSS Statistics Data Editor (New York, NY) and Microsoft Excel (Redmond, WA) were used for statistical analyses.
Results
The demographic and clinical characteristics of the study cohort are summarized in Table I . One hundred eight patients underwent 118 operations. Eight patients underwent >1 operation. In 51 patients (47%), a germline mutation was detected. In 17 of the 51 patients (33%) with a germline mutation (1 VHL, 1 FH, 2 RET, 1 SDHA, and 11 SDHB) there was no family history of PC/PGL or family members with a positive genetic testing result.
In 76 operations (65%), it was the first operative intervention for the disease site, 60 of which were performed with a laparoscopic approach, and 17 with an open approach (Fig 1) . Forty-one operations (35%) were reoperative interventions, 36 of which were open and 5 were laparoscopic. Twenty-five patients (17 no germline mutation, 5 SDHB, 1 SDHA, 1 VHL, and 1 RET) underwent an operation for metastatic disease. In patients with functional tumors, 79% of the operations resulted in biochemical remission. Factors associated with a higher risk of persistent/recurrent disease on biochemical testing were an open surgical approach (P < .001), presence of metastatic disease (P < .001), reoperations (P < .001), and male sex (P < .05), but not age, body mass index, and presence of germline mutation.
Minimally invasive versus open surgical approaches for initial operative interventions
The demographic and clinical characteristics of 76 patients who underwent PC/PGL resection as their initial operation are summarized in Table II . A germline mutation in susceptibility genes was present in 39 patients. Twenty-nine patients with a germline mutation (8 VHL, 14 RET, 4 SDHB, 1 NF1, 1 MAX, and 1 MEN1) underwent minimally invasive surgery and 10 (7 SDHB, 1 SDHA, 1 SDHD, 1 VHL) underwent an open operation. The average tumor size in patients who underwent a minimally invasive approach was significantly smaller than those of patients who had an open surgery (3.9 vs 5.8 cm, P < .01). Clinical characteristics associated with whether an open or laparoscopic approach was used were tumor size (P < .01) and presence of germline mutation in known susceptibility genes (P < .05). Comparing patients with a germline mutation in RET, VHL, or NF1 with the rest of the cohort undergoing an initial operation, patients with the aforementioned mutations were more likely to undergo a minimally invasive approach (P < .05). Comparing patients with a known SDHB mutation with the rest of the cohort whose surgery was their initial operative intervention for that site of disease, patients with SDHB mutation were more likely to undergo an open surgical approach (P < .01) on multivariate analysis (Table II) .
In patients who had their first-time operation for a PGL (8 SDHB, 2 VHL, and 4 unknown mutation), all of patients with VHL mutation had a laparoscopic approach, whereas 7 out of 8 (87.5%) patients with SDHB mutation had an open approach.
In 12 patients (31%) with a germline mutation, (6 SDHB, 3 RET, 1 NF1, 1 VHL, and 1 SDHA), there was no significant family history of PC/PGL. Out of the 6 patients with SDHB mutation, 2 patients presented with PC as their first disease manifestation, 2 patients presented with pelvic PGL, and 2 patients had a history of PC/PGL resection. One of the patients with RET mutation had a history of thyroidectomy for medullary thyroid carcinoma and 2 presented with concurrent medullary thyroid carcinoma. The patient with NF1 had a history of neurofibromas, while the patient with VHL had previous resection of PCs and presented with a PGL. The patient with SDHA mutation presented with metastatic PC/PGL. One patient (2%) with no known germline mutation had a family history of PC/PGL.
Cortical-sparing adrenalectomy
Sixty-eight adrenal operations were performed, 12 of which were bilateral adrenalectomy during the same operation. Fifty-four patients (79%; 33 with no known germline mutation, 7 RET, and 3 SDHB) underwent a total adrenalectomy and 14 patients (21%) underwent a cortical-sparing adrenalectomy (Fig 2) . Five out of 14 patients underwent a unilateral total and contralateral corticalsparing adrenalectomy, 3 patients underwent bilateral corticalsparing adrenalectomies, and 2 patients had a history of previous contralateral total adrenalectomy and underwent a corticalsparing adrenalectomy. Four out of 54 patients had bilateral total adrenalectomy. Three patients (1 RET, 1 MAX, and 1 no known germline mutation) had a history of a contralateral total adrenalectomy and 1 patient (NF1) had a history of bilateral partial adrenalectomy. The average tumor size of patients who underwent a total adrenalectomy was 4.47 cm and 2.36 cm (P < .05) for patients who underwent a cortical-sparing adrenalectomy. Out of the 54 patients who underwent a total adrenalectomy, 18 had a germline mutation (7 RET, 3 SDHB, 2 VHL, 2 NF1, 1 SDHA, 1 SDHD, 1 MAX, and 1 MEN1). Out of the 14 patients who underwent a cortical-sparing adrenalectomy, 13 (93%) had a germline mutation (7 RET, 5 VHL, and 1 SDHB). The patient with SDHB mutation had bilateral adrenal lesions, the right measuring 1.2 cm and the left measuring 0.7 cm. The patient underwent a left partial adrenalectomy to avoid adrenal insufficiency.
Variables significantly associated with a cortical-sparing adrenalectomy being performed were age (P < .05), presence of germline mutation (RET, NF1, and VHL, P < .01), and tumor size (P < .05; Table III ). The presence of a germline mutation and tumor size remained statistically significant on multivariate analysis. Thirteen out of 14 patients undergoing cortical-sparing adrenalectomy had functional tumors and achieved biochemical cure, and one patient had ¶ One patient had elevated plasma epinephrine and dopamine while urinary studies were within normal limits. The other patient underwent bilateral adrenalectomy, and 1 month later continued to have elevated urinary norepinephrine and normetanephrine; 2 months later, plasma norepinephrine remained elevated with no evidence of recurrent disease noted on FDG PET/CT.
‖ Both patients underwent a palliative resection in a setting of skeletal metastatic disease. BMI, body mass index; FDG, fluorodeoxyglucose.
no follow-up information available. In patients who had corticalsparing adrenalectomy, 80% of the patients had adequate adrenocortical function based on postoperative adrenocorticotropic hormone (ACTH) stimulation testing (Table IV) .
Rate of germline mutation and impact of preoperative genetic testing data on operative intervention in patients without a family history PC/PGL
Although we found an association between the presence of germline mutation and the operative approach and extent of adrenalectomy, we wanted to determine the rate of germline mutation in which patients had no known inherited syndrome until the preoperative genetic testing results and how this impacted our surgical management. Seventeen (15.7%) patients were found to have a germline mutation in a PC/PGL susceptibility gene without any family history or a personal history to suggest an inherited syndrome. In 10 patients (6 SDHB, 2 RET, 1 VHL, 1 SDHA), it was their first operation for tumor site and in 7 patients (5 SDHB, 1 FH, 1 RET) it was a reoperation. In 3 patients, a minimally invasive approach was used patients underwent operations involving adrenal gland Patient were given 250 μg of ACTH and cortisol measured at baseline (before administration of ACTH, 0 minutes) and at 30 and 60 minutes. Seven patients underwent a unilateral cortical-sparing adrenalectomy and contralateral total adrenalectomy, while 3 patients underwent a bilateral cortical-sparing adrenalectomy. Four out of 10 patients had adrenal insufficiency in the immediate postoperative period, while only 2 out of 10 (20%) had persistent adrenal insufficiency. Two patients did not undergo an ACTH stimulation test prior to discharge, one of whom had normal cortisol level while the other patient was discharged with empiric hydrocortisone replacement and was successfully weaned off the medication. POD, postoperative day.
even though the PC was large or it was a PGL based on the preoperative germline mutation. Two patients with a germline RET mutation had a laparoscopic adrenalectomy even though their tumors measured 9.5 and 8 cm in greatest diameter because of the low risk of metastases/malignancy. A patient with a VHL germline mutation had laparoscopic resection of a PGL. Five patients had an open surgical approach because they had a germline SDHB or FH mutation.
Discussion
There have been significant advances in our understanding of the pathobiology and imaging modalities to detect PC/PGL. The rarity of PC/PGL calls for a multidisciplinary approach to each patient involving endocrinologists, surgeons, medical oncologists, and genetic counselors to optimize patient outcome. There is limited data and no prospective study on the impact of preoperative genetic testing information on surgical management of patients with PC/PGL. Thus, we analyzed demographic, clinical, and genetic factors that could influence the surgical management of PC/PGL. We found that the presence of germline mutation and tumor size were significantly associated with the surgical approach used (open versus minimally invasive approaches) and the extent of adrenalectomy (total versus cortical-sparing adrenalectomy). Most importantly, 15.7% of our study cohort had no family history and tested positive for a germline mutation in a susceptibility gene preoperatively. This genetic data did impact the surgical approach and extent of resection in 15 of the 108 patients in our study.
In recent guidelines, genetic testing for common susceptibility genes has been recommended. In the 2014 Endocrine Society Clinical Practice Guidelines, genetic testing is recommended based on a clinical feature driven diagnostic algorithm. 5 In a more recent practice guideline by the European Society of Endocrinology, genetic testing also is recommended in all patients with PC/PGL. 5, 6 However, in neither clinical practice guideline is routine preoperative genetic testing clearly addressed or recommended in all patients with PC/ PGL. In our study cohort, 33% of the patients with a germline mutation did not have any family history of an inherited syndrome, and 36% of the patients with SDHB germline mutations had no family history and had no previous history of PC/PGL on presentation.
Advances in genomic medicine with next-generation sequencing has allowed for rapid, accurate, and more cost-effective testing for cancer susceptibility genes including susceptibility genes for PC/PGL. 7 Important genotype-phenotype associations in PC/PGL have been characterized and have important implications in the clinical management of PC/PGL. For example, Castinetti et al showed in a multicenter, multinational study that in patients with RET germline mutations the rate of malignancy was extremely low, and that 44% of patients presented with bilateral PC at the initial presentation. 8 Thus, this data would suggest that cortical-sparing adrenalectomy in patients with germline mutations in RET would be reasonable if there are no clinical signs of malignancy. In another study by Aufforth et al, 9 who studied VHL-associated PCs/PGLs, 16% of the patients with PC presented with bilateral disease and 20% subsequently developed contralateral PC. Again, this also would suggest that corticalsparing adrenalectomies are warranted in patients with VHL to preserve cortical function and avoid lifelong steroid replacement and the risk of Addisonian crisis.
A minimally invasive surgical approach and cortical-sparing adrenalectomy is preferred in patients with specific germline mutations (NF1, RET, and VHL) associated with a low risk of malignancy. [7] [8] [9] In our study, we found that patients with large tumors and preoperative RET germline mutation testing result had successful laparoscopic adrenalectomy and a patient with a VHL germline mutation had a laparoscopic approach for a PGL because of the low risk of malignancy in these patients. In contrast, germline mutations in SDHB, TMEM127, or FH confer a higher risk of recurrence, presence of extra-adrenal disease, and/or metastatic disease. 6, [10] [11] [12] Therefore, an open surgical approach with regional lymphadenectomy probably is preferred in most patients with a high-risk tumor (positive SDHB, TMEM127, and FH), especially those with large primary tumors. 5, 10, 13 Although there is no randomized control trial to determine the optimal surgical approach, there is general agreement that large tumors that are potentially malignant should be resected using an open approach. 5, 6 Moreover, there have been reports associated with peritoneal seeding in patients who had laparoscopic resection for what likely were malignant tumors. 14, 15 We found that 4.6% of patients had a germline mutation in SDHB or FH without a family history and we used an open surgical approach in these patients because of the risk of malignancy.
We found that 80% of patients who had cortical-sparing adrenalectomy had adequate adrenocortical function and did not require steroid replacement. There are several factors that contribute to the decision and the ability to perform a cortical-sparing adrenalectomy. In our study cohort, the only factors that were statistically significant on univariate and multivariate analyses were the size of the tumor and germline mutation status in known susceptibility genes. The rate of adrenal insufficiency after cortical-sparing bilateral adrenalectomy reported in the literature is ≈20%, 16 which is similar to our study results. We performed partial adrenalectomy, leaving at least 30% of normal adrenal gland in-situ, which was not feasible in 11 patients with large or centrally located tumors, or tumors in close proximity to the adrenal vein, but that had germline mutations in RET, VHL, and NF1. Brauckhoff et al evaluated patients undergoing bilateral partial adrenalectomy and found that a remnant size of 15-30% of 2 normal adrenal glands was necessary to prevent adrenal insufficiency. 16 There are several limitations to our study. Although it was based on prospectively collected data, being a tertiary referral center may have created a selection bias for more patients having inherited syndromes. However, 60% of our cohort had no known germline mutation and 33% of the patients with germline mutation had no family history to suggest that referral of patients with a high predisposition to inherited PC/PGL accounts for our study findings. Although we found the type of surgical approach and extent of resection was impacted by the preoperative genetic testing result and a significant number of patients without a family history had a germline mutation found, we cannot determine if this data impacts patient outcome.
In conclusion, approximately half of patients with PC/PGL have a germline mutation and preoperative knowledge of the type of germline mutation, in addition to other clinical variables, affects the surgical approach and extent of adrenalectomy. Therefore, surgeons should request genetic testing information to make an informed surgical intervention.
Dr Quan Yang Duh (San Francisco, CA): This is a wonderful study. This has been something that we have always wanted for a long time that we wish when we do operations on pheos or paragangliomas, that we can have the genetic information ahead of time.
Practically speaking, however, when we ask for this type of genetic testing, it takes months to come back, and yet you have a patient in front of you. And my belief is that most of the time, knowing where the lesion is and how big it is and looking at what the CT scan is, dictates what you do.
So, can you tell me of the patients that you have, in retrospect, how many operations would you have done differently if you were to have the genetic testing before. Now at NIH, I bet you already have the genetic information, but I think this has to be tested in the real world, that out of a hundred patients, how many operations would you have changed? Because I think much of it is dictated by what it looks like. Dr Pavel J. Nockel: No, I agree. That is an excellent comment. In our case, we had genetic information preoperatively, so it would be a good study to see how many patients would have had a different approach, or different extent of adrenalectomy if the genetic information was not known. Although I cannot answer the question based on our cohort.
Dr Quan Yang Duh (San Francisco, CA): So perhaps we should put together a multi-institutional study of people that did not have mutation or analysis before, and then have it afterwards and see how many you would have done the operation differently? Dr Pavel J. Nockel: Yeah. Thank you. That would be great. Dr William B. Inabnet, III (New York, NY): As a follow up to Dr. Duh's question, I think tumor location is very important when deciding the operative approach. In your cohort, you really lump together adrenal and paraganglioma, but they are very different. For example, paragangliomas at the aortic bifurcation with an SDHB mutation can be very difficult to approach sometimes laparoscopically because of vascularity, et cetera. So, in your analysis, did you separate and substratify the paragangliomas from the adrenal operations with regards to minimally invasive versus open approach? Dr Pavel J. Nockel: I did do that analysis. I am sorry. I do not have that presented. I did not find it to be statistically significant. But there probably are other factors that played a role and caused the lack of statistical significance.
Dr Christopher P. McHenry (Cleveland, OH): Congratulations on a very nice presentation. I wondered if you might clarify one thing for me.
On your graph, when you looked at the cortical sparing adrenalectomies, it seemed to me that you still had a patient in the succinate dehydrogenase isoenzyme B that underwent a cortical sparing adrenalectomy. Number one, can you clarify that for me?
And, 2, should we be doing that operation in somebody that has a, you know, succinate dehydrogenase isoenzyme B mutation? Dr Pavel J. Nockel: That is a great observation. Yes, we had one patient who presented with bilateral adrenal tumors. One side of it was 1.5 cm and the other side was approximately .6 cm, so given the small size in that one patient, they did undergo a partial adrenalectomy on the side of the 0.6 -mm tumor. And it was included in analysis.
Since this was a retrospective analysis, you cannot draw a conclusion of whether that should be done or not. But in that patient, it was successfully done. Although for the 1.5-cm tumor, they underwent a total adrenalectomy. Dr Christopher R. McHenry (Cleveland, OH): So tomorrow if you got a patient that has a paraganglioma, a small paraganglioma and they have an SDHB mutation, would you do a cortical sparing adrenalectomy? Dr Pavel J. Nockel: No, I would not. In that patient, it was done to avoid adrenal insufficiency, but for the cancer operation, I would do a total.
Dr Paul H. Graham (Houston, TX): Thank you for your paper.
My quick question, as you noted, some mutations have a high propensity for bilateral tumors. And how many, if any, of your sample were bilateral tumors that were simultaneous and how did that account for the approach in your case series? Dr Pavel J. Nockel: We had approximately 30% of the patients that had bilateral synchronous or metachronous disease. It did not play out to be statistically significant when we took that factor for our analysis, but definitely preoperatively it is something that we think about and try to preserve as much adrenal function as possible, given the bilateral disease.
Dr Electro Kebebew (Bethesda, MD): I just wanted to clarify a few things. Great job, Pavel.
Quan's question, impossible to do that study retrospectively. In regards to how did it impact the surgical approach, I do not believe it is a rational study. I think the more important question is, do we improve the outcome of the patients by having this information?
Barry had asked about extraadrenal paragangliomas. We do approach those minimally invasive if it is technically possible. And then the other question in regard to the SDHB, I think if the patient is in active surveillance program and they have a very small tumor, very reasonable to do a partial adrenalectomy
